Phase 3b Study of CERVAVAC® Vaccine in Women Living with HIV Initiated
A Phase 3b clinical study is underway to evaluate the immunogenicity and safety of the SIIPL qHPV vaccine CERVAVAC® in women living with HIV aged 15-25 years.
Phase III
Oncology / HPV
Status
Initiated
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of Phase 3b study for the CERVAVAC® vaccine in women living with HIV is significant as it targets a high-risk population that could benefit greatly from HPV vaccination. Successful outcomes may enhance Serum Institute of India's competitive positioning in the HPV vaccine market and influence vaccination strategies for vulnerable groups.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor results from the Phase 3b study and any subsequent regulatory actions or market uptake in India and other regions.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.